PROFESSIONS, VOCATIONS, AND BUSINESSES
54-1770. notification of drug product selection for epilepsy and seizure drugs. The provisions of this section shall be null, void, and of no force and effect on and after July 1, 2021.
(1) In this section:
(a) "Anti-epileptic drug" means:
(i) A drug used for the treatment of epilepsy; or
(ii) A drug used to treat or prevent seizures.
(b) "Drug product selection" means the selection of a therapeutically equivalent drug, including a generic version for the prescribed brand, a branded version for the prescribed generic, or a generic version by one (1) manufacturer for a generic version by a different manufacturer.
(c) "Epilepsy" means a neurological condition characterized by recurrent seizures.
(d) "Seizure" means an acute clinical change secondary to a brief disturbance in the electrical activity of the brain.
(2) When a prescriber has specified that a drug is prescribed for the treatment of epilepsy or seizures, pharmacy personnel who perform drug product selections shall:
(a) Notify the prescriber of such drug product selection via facsimile, telephone message or any other appropriate means to the prescriber’s place of business; and
(b) Provide the patient or the patient’s representative with notification of the selection.
(3) Nothing in this section shall delay the dispensing of a valid prescription for an anti-epileptic drug.
[54-1770, added 2010, ch. 277, sec. 1, p. 717; am. 2019, ch. 25, sec. 16, p. 51.]